Conference Correspondent

Gilteritinib plus azacitidine led to significantly higher composite complete remission rates but did not provide a survival advantage compared with azacitidine alone in patients with newly diagnosed FLT3^mut+ AML ineligible for intensive induction chemotherapy. Read More ›

In a retrospective analysis, upfront liposomal daunorubicin/cytarabine treatment was shown to accord an overall survival advantage compared with HMA + venetoclax, which, however, did not extend to complete response rates and recurrence-free survival. Read More ›

Results from an ongoing first-in-human phase 1/2 study indicated that the FLT3/SYK inhibitor HM43239 yielded a favorable safety profile and encouraging antileukemic activity in patients with relapsed/refractory AML regardless of FLT3 mutation status. Read More ›

Findings from a retrospective analysis suggested that venetoclax plus hypomethylating agent plus an FLT3 inhibitor led to significant improvement in clinical outcomes, in older and unfit patients with FLT3-mutated AML. Read More ›

Patients with treated secondary AML and prior hypomethylating exposure derived significant clinical benefit from hypomethylating agents plus venetoclax therapy compared with chemotherapy-based approaches. Read More ›

Conditioning regimens for allo-HSCT includes either myeloablative conditioning or reduced-intensity conditioning. The use of fludarabine/busulfan appears to deliver better patient outcomes after transplant compared with other commonly used conditioning regimens. Read More ›

Clinical trials have demonstrated JAK2 inhibition with fedratinib effectively reduces spleen volume and improves symptoms in patients with myelofibrosis. It has yet to be determined whether spleen size before fedratinib therapy influences these effects. Read More ›

Low-dose ruxolitinib is an approved therapy for patients with myelofibrosis who have thrombocytopenia, but efficacy may be limited. Evidence from PERSIST-2 indicate pacritinib at full dose may provide additional clinical benefit with a similar safety profile compared with ruxolitinib. Read More ›

Pacritinib is currently under investigation in multiple trials and demonstrated efficacy and safety in patients with advanced myelofibrosis during the study period. Patients who continue pacritinib on a compassionate-use basis show further improvement in clinical outcomes. Read More ›

Patients with myelofibrosis who are refractory to JAK inhibitors often lack effective treatment options that not only manage symptoms but can also reduce disease progression. Navtemadlin may improve disease burden in these patients through disease modification. Read More ›